Benefits And Risks of Vildagliptin/Metformin Versus Sulphonylureas/Metformin Combination Therapy In Type 2 Diabetes Mellitus (T2dm) From Patient’s Perspective- Real-World Data
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2140
https://www.valueinhealthjournal.com/article/S1098-3015(15)04216-3/fulltext
Title :
Benefits And Risks of Vildagliptin/Metformin Versus Sulphonylureas/Metformin Combination Therapy In Type 2 Diabetes Mellitus (T2dm) From Patient’s Perspective- Real-World Data
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04216-3&doi=10.1016/j.jval.2015.09.2140
First page :
A615
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1553